Zydus Cadila gets USFDA nod for anti-depressant
Drug firm Zydus Cadila has received the US Food and Drug Administration ’s nod to market Mirtazapine, an anti-depressant, in the American market
Latest News »
- Global gold prices stay steady ahead of speech by US Fed’s Janet Yellen
- Google braces for EU ruling that may slow shopping ad boom
- US clears sale of Guardian drones to India
- Tejas Networks shares rise 2.7% on stock market debut
- Trump accepts Narendra Modi’s invite for India visit, commits to India-US ties
New Delhi: Drug firm Zydus Cadila has received the US health regulator’s nod to market Mirtazapine, orally disintegrating tablets, an anti-depressant, in the American market.
Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market the Mirtazapine tablets USP in strengths 15mg, 30mg and 45mg, the company said in a BSE filing. The company will manufacture the product at its facility in Baddi.
The Gujarat-based group has more than 115 approvals and has filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
Shares of Cadila Healthcare, the group’s listed entity, were trading at Rs495.60 per scrip on BSE, up 0.21% from its previous close.